Navigation Links
Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
Date:6/5/2013

HAYWARD, Calif., June 5, 2013 /PRNewswire/ -- Rafael Simon, a veteran in the environment and energy industries, has joined Microvi Biotechnologies as Chairman of its Board of Directors. Rafael was the COO of Zenon Environmental, a leading water treatment company, previous to its acquisition by GE Water in 2006 for nearly $700 M.

(Photo: http://photos.prnewswire.com/prnh/20130605/PH26398 )

While at Zenon, Rafael was responsible for all aspects of sales, operations, R&D and manufacturing. During his tenure at Zenon, share price tripled and he was named Canada's top COO by Canadian Business, Canada's leading business magazine.

"Rafael brings expertise in strategy and a depth of knowledge in our market focus that will be important in Microvi's continuing commercialization of its MicroNiche Engineering Platform Technology," said Dr. Fatemeh Shirazi , CEO of Microvi. "I am delighted to welcome him as Chairman of Microvi's Board of Directors."

He joins Microvi at a pivotal growth period, building on successful scaling and commercialization of the company's platform technology and various biocatalytic solutions for clean water, renewable biofuels, biochemicals and other industrial bioprocesses.

"I'm excited to have the opportunity to help scale-up the revolutionary Microvi biocatalyst technology which has the potential to disrupt so many industries," said Rafael.

Previous to his work with Zenon, Rafael worked at McKinsey & Company specializing in corporate growth strategies for water and energy companies.  Rafael currently serves as director on a number of boards internationally and received his Ph.D. in Materials Science and Mineral Engineering from the University of California, Berkeley.

About Microvi

Microvi is a leading biotechnology company that discovers, develops, manufactures, and commercializes innovative biocatalytic technologies in water, energy and chemical industries. Microvi's pipeline of solutions, created using its proprietary MicroNiche Engineering™ platform, enable cost-effective economics, are energy efficient and waste free and deliver higher performance than conventional methods. To learn more please visit www.microvi.com.

Media Contact:

Karin Kidder , Microvi Biotechnologies, 1-510-344-0668
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Microvi
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Microvi and Aquatech Break Ground on Large Demonstration System at Aerojet Site in Rancho Cordova, CA
2. Dr. Gerald Jerry Zon Launches New Blog for TriLink BioTechnologies
3. TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S, Copenhagen, Denmark
4. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
5. TriLink BioTechnologies Awards Keck Science Department ResearchReward
6. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
7. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
8. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
9. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
10. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
11. PTC Therapeutics Appoints Shane Kovacs as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... announced today that they have entered into a multiyear collaboration to identify and ... researchers with additional tools for gene editing across all applications. , Under the ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract research, ... improve patient outcomes and quality of life, will now be offering its impurity ... to new regulatory requirements for all new drug products, including the finalization of ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):